Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.180
-0.015 (-1.26%)
Sep 26, 2025, 4:00 PM EDT - Market closed

Rein Therapeutics Stock Forecast

RNTX's stock price has decreased by -63.24% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Rein Therapeutics stock has a target of 10, which predicts a 747.46% increase from the current stock price of 1.18.

Price Target: $10.00 (+747.46%)
Analyst Consensus: Buy
Target Low Average Median High
Price $10 $10 $10 $10
Change +747.46% +747.46% +747.46% +747.46%

Analyst Ratings

The average analyst rating for Rein Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Aug '25Sep '25
Strong Buy 01
Buy 00
Hold 11
Sell 00
Strong Sell 00
Total 12

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Initiates
$10
Strong Buy Initiates $10 +747.46% Sep 22, 2025
Brookline Capital
Brookline Capital
Hold
Downgrades
n/a
Hold Downgrades n/a n/a Aug 19, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.94
from -3.51
EPS Next Year
-0.55
from -0.94
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026
Revenue
-------
Revenue Growth
-------
EPS
-12.14-5.89-6.02-3.42-3.51-0.94-0.55
EPS Growth
-------
Forward PE
-------
No. Analysts
-----33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 202520262027
High n/a n/a
Avg n/a n/a
Low n/a n/a

Revenue Growth

Revenue Growth 202520262027
High - -
Avg - -
Low - -

EPS Forecast

EPS 202520262027
High -0.97 -0.57
Avg -0.94 -0.55
Low -0.90 -0.53

EPS Growth

EPS Growth 202520262027
High - -
Avg - -
Low - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.